

Special Issue

Stem Cell Transplantation in Cancer Treatment: Current Status and Future Direction

Message from the Guest Editors

Stem cell transplantation (SCT) has emerged as a well-established treatment for various malignant and non-malignant diseases of hematopoietic origin. In recent years, improvements in transplantation techniques have led to a significant reduction in treatment-related complications. Importantly, mortality rates have declined in recent decades, despite increasing numbers of older patients and those with more comorbidities undergoing allogeneic HSCT. This Special Issue focuses on the role of SCT in challenging cancer treatment options, covering both basic research and more clinical aspects that may advance our understanding of this intriguing process.

Guest Editors

Prof. Dr. Claudio Cerchione

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, 47014 Meldola, Italy

Dr. Giovanni Martinelli

IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", 47014 Meldola, FC, Italy

Deadline for manuscript submissions

closed (2 February 2024)



Hematology Reports

an Open Access Journal
by MDPI

Impact Factor 1.2
CiteScore 1.4
Indexed in PubMed



mdpi.com/si/131299

Hematology Reports
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
hematolrep@mdpi.com

[mdpi.com/journal/
hematolrep](https://mdpi.com/journal/hematolrep)





Hematology Reports

an Open Access Journal
by MDPI

Impact Factor 1.2
CiteScore 1.4
Indexed in PubMed



[mdpi.com/journal/
hematolrep](https://mdpi.com/journal/hematolrep)



About the Journal

Message from the Editor-in-Chief

Hematology is a rapidly evolving discipline, central to understanding and treating disorders of the blood. *Hematology Reports* aims to provide an open platform for researchers and clinicians to share findings, insights, and innovations with the global scientific community. We encourage submissions that enhance clinical knowledge of blood disorders and their clinical management, from basic biology to translational and clinical studies. Through fostering collaboration and discussion, the journal seeks to advance knowledge and support improvements in both research and clinical practice.

Editor-in-Chief

Prof. Dr. Claudio Cerchione

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, 47014
Meldola, Italy

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, ESCI (Web of Science), PMC, PubMed, Embase, and other databases.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 29.4 days after submission; acceptance to publication is undertaken in 4.6 days (median values for papers published in this journal in the second half of 2025).